Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARDBiotechnology
+$0.09 today
- Market cap
- $86.45M
- Beta
- 4.47
- P/E (TTM)
- -1.2
- EPS (TTM)
- -$3.20
Volume 1.32M
Average 0.18M
AARD Total Debt
Short-term and long-term borrowings combined.
Aardvark Therapeutics, Inc. Common StockNASDAQ: AARD
Total Debt · Q1 FY2026 · quarter ended Mar 2026
Total debt falls 53.7% from a year ago
Total debt stood at $336K at the end of Q1 FY2026, down 53.7% from a year earlier and down 23.8% from the prior quarter. Over 3 fiscal years it compounded at +19.0% a year.
Context
- Total debt amounted to 0.3% of total assets at the end of Q1 FY2026, down 0.1 pp from a year earlier.
- Total debt increased in 1 of the last 3 fiscal years.
What to watch
Whether total debt keeps falling in the next quarterly balance sheet after a -53.7% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Debt history
USD · from the balance sheet
- Latest · FY2025
- 441K USD
- Year-over-year change
- -43.4%
- 3-year CAGR
- +19.0%
| Period | Period end | Total Debt | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 441K | -43.4% |
| FY2024 | 2024-12-31 | 779K | +380.9% |
| FY2023 | 2023-12-31 | 162K | -38.2% |
| FY2022 | 2022-12-31 | 262K | — |
Total Debt vs competitors
How AARD compares with its peers on the latest reported figures
- AARD's Mar 2026 total debt of $336K is the 10th highest of the 11 companies compared; the peer median is $14.19M.
- Its year-over-year change of -53.7% is the lowest of 10, against a peer median of -1.6%.
- Total debt amounts to 0.3% of total assets for AARD, versus a peer median of 11.9%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $186.62M | -13.7% | +96.0% | 59.3% | |
| Mar 2026 | $41.99M | +20.5% | -7.1% | 18.9% | |
| Mar 2026 | $28.87M | -1.6% | -0.3% | 16.2% | |
| Mar 2026 | $26.95M | +2.8% | -0.6% | 18.1% | |
| Mar 2026 | $18.26M | -8.0% | -0.4% | 28.4% | |
| Mar 2026 | $10.12M | -21.6% | -10.5% | 7.5% | |
| Mar 2026 | $2.49M | -17.5% | -8.8% | 1.1% | |
| Mar 2026 | $2.33M | +190.6% | -50.4% | 2.3% | |
EPRXEupraxia Pharmaceuticals Inc. | Mar 2026 | $2.01M | +3715.1% | -76.7% | 1.4% |
| Mar 2026 | $336K | -53.7% | +19.0% | 0.3% | |
ZURAZura Bio Limited | Mar 2026 | $0 | — | — | 0.0% |
| Peer median (excluding AARD) | $14.19M | -1.6% | -7.1% | 11.9% | |
Competitors are the stored peer set for AARD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Aardvark Therapeutics, Inc. Common Stock
NASDAQ:AARD
Intrinsic Alpha fair value
Locked
Current Price
$3.95
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.